Survival analysis of post-operatively treated cancer gall bladder patients with Adjuvant Chemo-radiotherapy: an institutional study

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter S. Saugat
Citation Annals of Oncology (2016) 27 (2): 86-101. 10.1093/annonc/mdw201
Authors S. Saugat1, H. Kumar2, N. Sharma2, M. Singhal2, S. Beniwal2, P. Kumari2, S. Narayan2, A. Kapoor3, S. Jakhar2, S. Maharia2, R. Nirban2
  • 1ATRCTRI, Bikaner, India, /
  • 2Acharya Tulsi Regional Cancer Treatment and Research Center, Bikaner, India, /
  • 3Acharya Tulsi Regional Cancer Treatment and Research Institute, Bikaner, India, /

Abstract

Background: Gall bladder carcinoma (GBC) is considered the fifth most common one of the most aggressive gastro intestinal tract malignancies. Over the years surgical resection has been considered the only curative treatment of these tumours. Even after curative surgery, survivals are dismal and loco-regional failure accounts for 40-86%. Although these are considered radio-resistant, adjuvant radiation, with or without chemotherapy, has been tried to improve loco-regional control and overall survival rates. With an aim to evaluate acute and late toxicity and efficacy of adjuvant chemo-radiation (CRT) after curatively resected GBC.